



## **ObsEva SA to Attend Needham Annual Healthcare Conference in NYC**

**Geneva, Switzerland – 24 March 2017** – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder and Tim ADAMS, CFO, will attend the 16<sup>th</sup> Annual Needham Healthcare Conference. Management will be presenting on Tuesday April 4 at 3:40 pm and will be hosting one-on-one meetings on April 4 and 5, 2017 at the Westin New York Grand Central Hotel.

### **About ObsEva**

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit [www.ObsEva.com](http://www.ObsEva.com).

###

### **Media Contact:**

Liz Bryan  
Spectrum Science  
[lbryan@spectrumscience.com](mailto:lbryan@spectrumscience.com)  
202-955-6222 x2526

### **Company Contact:**

Delphine Renaud  
ObsEva, CEO Office  
[delphine.renaud@obseva.ch](mailto:delphine.renaud@obseva.ch)  
+41 22 552 1550